Protalix Bio's OPRX-106 shows positive action in mid-stage UC study; shares up 5% premarket [Seeking Alpha]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Seeking Alpha
Protalix Bio's OPRX-106 shows positive action in mid-stage UC study; shares up 5% premarketNano cap Protalix BioTherapeutics (NYSEMKT:PLX) is up5% premarket on increased volume in response to itsannouncement of updated results from a Phase 2 clinical trial assessing OPRX-106 in patients with moderately active ulcerative colitis (UC).In 24 patients who received either a daily oral 2 mg or 8 mg dose of OPRX-106 for eight weeks, the clinical response rate was 67% including 28% who experienced clinical remission. 72% showed improvements in rectal bleeding scores.Complete results will be submitted for presentation at a future medical conference.OPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to a protein called IgG1 Fc. The company says the plant cells function as a natural delivery capsule they pass through the digestive tract by virtue of their cellulose cell walls.Previously:Protalix up 9% premarket on positive interim data on OPRX-106 in UC
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics, Inc. (NYSE: PLX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 [Yahoo! Finance]Yahoo! Finance
PLX
Earnings
- 11/6/23 - Beat
PLX
Sec Filings
- 4/3/24 - Form 4
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- PLX's page on the SEC website